Average Co-Inventor Count = 3.64
ph-index = 12
The patent ph-index is calculated by counting the number of publications for which an author has been cited by other authors at least that same number of times.
Company Filing History:
1. Corixa Corporation (47 from 247 patents)
2. Celgene Quanticel Research, Inc. (4 from 106 patents)
3. Amgen Inc. (3 from 1,970 patents)
4. Celgene Corporation (1 from 549 patents)
55 patents:
1. 10960005 - Treatment of relapsed and/or refractory solid tumors and non-hodgkin's lymphomas
2. 10849898 - Treatment of relapsed and/or refractory solid tumors and non-Hodgkin's lymphomas
3. 10548896 - Treatment of relapsed and/or refractory solid tumors and non-Hodgkin's lymphomas
4. 10543213 - Treatment of relapsed and/or refractory solid tumors and non-hodgkin's lymphomas
5. 10465009 - BCMA antigen binding proteins
6. 10328077 - Treatment of relapsed and/or refractory solid tumors and non-hodgkin's lymphomas
7. 10220090 - BCMA Antigen binding proteins
8. 9243058 - BCMA antigen binding proteins
9. 8182823 - Compositions and methods for the therapy and diagnosis of breast cancer
10. 7939646 - Compositions and methods for the therapy and diagnosis of prostate cancer
11. 7855271 - Compositions and methods for the therapy and diagnosis of breast cancer
12. 7598226 - Compositions and methods for the therapy and diagnosis of breast cancer
13. 7517952 - Compositions and methods for the therapy and diagnosis of prostate cancer
14. 7270980 - Compounds for immunodiagnosis of prostate cancer and methods for their use
15. 7202342 - Compositions and methods for the therapy and diagnosis of prostate cancer